Condition: Diabetes


Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor

OBJECTIVE To assess the efficacy of Sativex, a cannabis-based medicinal extract, as adjuvant treatment in painful diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS In this randomized controlled trial, 30…

The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease

Abstract Background and Aims: The synthetic atypical cannabinoid Abn-CBD, a cannabidiol (CBD) derivative, has been recently shown to modulate the immune system in different organs, but its impact in obesity-related meta-inflammation…

Vascular responses disrupted by fructose-induced hyperinsulinemia improved with delta-9- tetrahydrocannabinol

  Abstract INTRODUCTION: In recent years, cannabinoids have been shown to have beneficial effects on diabetic vascular complications. Vascular complications due to fructose-induced hyperinsulinemia (HI) and diabetic vascular complications have…

Oxidative Stress Status in Testis of Type-2 Diabetic Rats Treated with Delta-9-Tetrahydrocannabinol

Abstract Objective: Type-2 diabetes (T2D) is a multifactorial disease that occurs as a result of impaired insulin secretion and increased glucose. Researchers emphasize that oxidative stress prevention and improvement strategies…

Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice

Abstract Anti-inflammatory and antidiabetogenic properties have been ascribed to cannabidiol (CBD). CBD-based medicinal drugs have been approved for over a lustrum, and a boom in the commercialization of CBD products…

Evaluation of cannabidiol’s inhibitory effect on alpha-glucosidase and its stability in simulated gastric and intestinal fluids

Abstract Objective Cannabidiol (CBD) has been reported to have anti-diabetic effects in pre-clinical and clinical studies but its inhibitory effects on α-glucosidase, a carbohydrate hydrolyzing enzyme, remain unknown. Herein, we…

Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action

Please use this link to access this publication. Abstract Cannabidiol (CBD), a phytocannabinoid compound, presents antidepressant and anxiolytic-like effects in the type-1 diabetes mellitus(DM1) animal model. Although the underlying mechanism…

Cannabinoid Receptors in Metabolic Regulation and Diabetes

Abstract There is an urgent need for developing effective drugs to combat the obesity and Type 2 diabetes mellitus epidemics. The endocannabinoid system plays a major role in energy homeostasis….

Cannabis and metformin on diabetic male Wistar rat sperm and reproductive organ parameters

Please use this link to access this publication Abstract Purpose Cannabis use has reportedly increased in type 2 diabetic users as a possible co-treatment for associated pain and inflammation. Both…

Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage

Abstract The atypical cannabinoid Abn-CBD improves the inflammatory status in preclinical models of several pathologies, including autoimmune diseases. However, its potential for modulating inflammation in autoimmune type 1 diabetes (T1D) is unknown. Herein we…